Nisha Pandey

Health and Me

Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In  Trial

A combination of two cancer drugs cut the risk of death by 58% in people who have advanced small cell <a href="https://www.healthandme.com/health/lung-cancer">lung cancer</a>, an aggressive form of the disease, according to results from a Phase 3 clinical trial.

The combination pairs Imdelltra (tarlatamab), developed by Amgen, with Imfinzi (durvalumab), an immunotherapy made by AstraZeneca.

In the DeLLphi-305 trial, patients who received both drugs lived a median of 21.1 months, compared to 12.7 months among those who received Imfinzi alone. 

The findings were presented at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 24, 2026, and published in The New England Journal of Medicine.

<h2>More About Imdelltra-Imfinzi Trial </h2>

Also read: <a href="https://www.healthandme.com/health-wellness/1-in-5-us-lung-cancer-patients-never-smoked-report-highlights-hidden-risk-factors-article-156400245" data-type="tilCustomLink">1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors</a>

The results indicated that using tarlatamab earlier in treatment could be beneficial. It is currently approved in the United States for adults with extensive-stage small cell <a href="https://www.healthandme.com/health-wellness/rising-aqi-in-delhi-ncr-doctors-warn-of-lung-and-heart-risks-as-pollution-builds-article-156382132" data-type="tilCustomLink">lung cancer</a> that has progressed during or after platinum-based chemotherapy.

The trial examined its application as a maintenance treatment after patients had completed initial chemotherapy and immunotherapy without their cancer progressing.

“For a disease where durable survival has remained extremely difficult to achieve, the magnitude and consistency of benefit in DeLLphi-305 are striking,” said Jacob Sands, an associate chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and an investigator in the trial.

The Phase 3 trial included 563 patients with extensive-stage small cell lung <a href="https://www.healthandme.com/health-wellness/colon-cancer-in-young-adults-the-growing-burden-among-indias-under-50-population-article-156335137" data-type="tilCustomLink">cancer</a> whose disease had not progressed after initial treatment with Imfinzi, platinum-based chemotherapy and etoposide. The main findings were:

- 58% lower risk of death: The combination reduced the risk of death compared to Imfinzi alone.

- 21.1 months median overall survival: This compared to 12.7 months in the Imfinzi-only group.

- Nearly 80% alive at one year: About 79% of patients receiving the combination were alive after 12 months, compared to 53% of those receiving Imfinzi alone.

- 66% lower risk of progression or death: Median progression-free survival was 7.4 months with the combination, versus 1.9 months with Imfinzi alone.

These results indicate that the combination improved both overall survival and the time patients lived without their cancer progressing. 

Also read: <a href="https://www.healthandme.com/health-wellness/i-never-recovered-from-that-crash-us-physicist-recalls-her-years-long-battle-with-long-covid-article-156393692" data-type="tilCustomLink">'I Never Recovered From That Crash': US Physicist Recalls Her Years-Long Battle With Long COVID</a>

Imdelltra, also known as tarlatamab, is a bispecific antibody that brings immune system T cells into contact with cancer cells, helping the immune system recognise and attack them.

Imfinzi, or durvalumab, blocks the PD-L1 protein, which some cancer cells misuse to evade immune attack.

The two drugs therefore target different aspects of the immune response. Researchers hope that combining them will improve the body's ability to control the cancer.

Jay Bradner, Amgen's executive vice-president of research and development, said, “These results represent an unprecedented advance for patients with extensive-stage <a href="https://www.healthandme.com/health-news/pope-leo-xiv-resumes-daily-activities-after-lung-cancer-surgery-how-recovery-looks-like-after-lung-lobe-removal-article-156342238" data-type="tilCustomLink">small cell lung cancer</a>, demonstrating a magnitude of survival benefit rarely seen in this aggressive disease.”

Why Can You Still Get COVID After Vaccination? Ex-CDC Vaccine Advisor Explains

Side effects related to grade 3 or higher treatment occurred in 20.9% of the patients who received the combination, compared to 10.8% of those receiving Imfinzi alone.

Cytokine release syndrome, an inflammatory reaction caused by immune system activation, occurred in 49.6% of patients who received Imdelltra. Most cases were mild or moderate, and one was classified as severe. No deaths were reported.

The findings provide evidence that adding tarlatamab to maintenance immunotherapy can extend survival in extensive-stage small cell lung cancer. The researchers also reported benefits among patients with brain or liver metastases.

Despite promising findings, researchers say that the trial focused on a particular cancer type and treatment. Regulatory authorities will need to examine the evidence adopting this combination for earlier stage of treatment.

Health Conditions A-Z

health

amgen-astrazenecas-new-treatment-combination-cuts-advanced-lung-cancer-death-risk-by-58-in-trial

amgen

Lung Cancer

astrazeneca

Imdelltra

tarlatamab

imfinzi

new england journal of medicine

european society for medical oncology

durvalumab

1-in-5-us-lung-cancer-patients-never-smoked-report-highlights-hidden-risk-factors

1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors

can-holding-your-urine-during-long-office-hours-or-traffic-jams-affect-urinary-health

Can Holding Your Urine During Long Office Hours or Traffic Jams Affect Urinary Health?

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

A combination of two cancer drugs cut the risk of death by 58% in people who have advanced small cell lung cancer, an aggressive form of the disease, according to results from a Phase 3 clinical trial.The combination pairs Imdelltra (tarlatamab), developed by Amgen, with Imfinzi (durvalumab), an immunotherapy made by AstraZeneca. In the DeLLphi-305 trial, patients who received both drugs lived a median of 21.1 months, compared to 12.7 months among those who received Imfinzi alone. The findings were presented at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 24, 2026, and published in The New England Journal of Medicine.More About Imdelltra-Imfinzi Trial Also read: 1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk FactorsThe results indicated that using tarlatamab earlier in treatment could be beneficial. It is currently approved in the United States for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy. The trial examined its application as a maintenance treatment after patients had completed initial chemotherapy and immunotherapy without their cancer progressing.“For a disease where durable survival has remained extremely difficult to achieve, the magnitude and consistency of benefit in DeLLphi-305 are striking,” said Jacob Sands, an associate chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and an investigator in the trial.The Phase 3 trial included 563 patients with extensive-stage small cell lung cancer whose disease had not progressed after initial treatment with Imfinzi, platinum-based chemotherapy and etoposide. The main findings were:- 58% lower risk of death: The combination reduced the risk of death compared to Imfinzi alone.- 21.1 months median overall survival: This compared to 12.7 months in the Imfinzi-only group.- Nearly 80% alive at one year: About 79% of patients receiving the combination were alive after 12 months, compared to 53% of those receiving Imfinzi alone.- 66% lower risk of progression or death: Median progression-free survival was 7.4 months with the combination, versus 1.9 months with Imfinzi alone.These results indicate that the combination improved both overall survival and the time patients lived without their cancer progressing. More About The Two DrugsAlso read: 'I Never Recovered From That Crash': US Physicist Recalls Her Years-Long Battle With Long COVIDImdelltra, also known as tarlatamab, is a bispecific antibody that brings immune system T cells into contact with cancer cells, helping the immune system recognise and attack them.Imfinzi, or durvalumab, blocks the PD-L1 protein, which some cancer cells misuse to evade immune attack.The two drugs therefore target different aspects of the immune response. Researchers hope that combining them will improve the body's ability to control the cancer.Jay Bradner, Amgen's executive vice-president of research and development, said, “These results represent an unprecedented advance for patients with extensive-stage small cell lung cancer, demonstrating a magnitude of survival benefit rarely seen in this aggressive disease.”               Side effects related to grade 3 or higher treatment occurred in 20.9% of the patients who received the combination, compared to 10.8% of those receiving Imfinzi alone.Cytokine release syndrome, an inflammatory reaction caused by immune system activation, occurred in 49.6% of patients who received Imdelltra. Most cases were mild or moderate, and one was classified as severe. No deaths were reported.The findings provide evidence that adding tarlatamab to maintenance immunotherapy can extend survival in extensive-stage small cell lung cancer. The researchers also reported benefits among patients with brain or liver metastases.Despite promising findings, researchers say that the trial focused on a particular cancer type and treatment. Regulatory authorities will need to examine the evidence adopting this combination for earlier stage of treatment.

amgen & astrazeneca's new treatment combination cuts advanced lung cancer death risk by 58% in trial

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In Trial

Cannabis Legalisation Linked To More Heart Attacks, Heart Failure Hospitalisations: Study Based On 50Mn Records

Swiss Team Including Indian Scientists Develops Electric Implant To Lower Blood Sugar Without Insulin Or Drugs

450 People In UP Get Anti-Rabies Shots After Drinking Milk From A Suspected Rabid Cow

Health Conditions A-Z

Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In Trial

1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors

Can Holding Your Urine During Long Office Hours or Traffic Jams Affect Urinary Health?